In Asthma, the levels of exhaled FeNO is correlated to sputum eosinophils particularly in the patient with poor controlled asthma or severe asthma. Moreover, the blood eosinophils had been studied that are also correlated to sputum eosinophils in similar patients group. According to well controlled asthma, althoug hin clinical practice guidelines recommend that the stepping down therapy should be considered to those patients due to the risks or costs of daily treatment, there is previous study has been shown that the airway hyperresponsiveness and sputum eosinophilia are predictors of loss of control during dose reduction. And, these tests are not readily available in primary care. However, there is limit number of clinical study to study the correlation of biologic markers among the patients with well controlled level before the stepping down management.
This is a single prospective trial. Enrollment will continue until 50 patients with well controlled asthma have been entered into this trial and have completed blood tests and spirometry. In this trial, the following parameters are to be evaluated: Blood eosinophils (absolute and relative) FeNO Pulmonary lung function test: FEV1, FVC, PF, MMEF 25-75%, % reversibility
Study Type
OBSERVATIONAL
Enrollment
84
Patients with well controlled asthma The following parameters are to be evaluated: Blood eosinophils FeNO Findings on lung function test
Narongwit Nakwan
Hat Yai, Changwat Songkhla, Thailand
Assessment of eosinophilic inflammation by correlating blood eosinophil count, FeNO measurement and lung function test
Correlation of FeNO, blood eosinophils, lung function test in patients with well controlled asthma before stepping down medication
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.